Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medication with broad cardiovascular benefits in those with type 2 diabetes, chronic kidney disease, and heart failure. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.